Alzheimer's disease failed clinical trials

Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective

(2021) Billy Dunn et al.   JAMA Internal Medicine

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

(2018) Martin R. Farlow et al.   JOURNAL OF ALZHEIMERS DISEASE

Inhibition of γ-Secretase Leads to an Increase in Presenilin-1

(2017) Aitana Sogorb-Esteve et al.   MOLECULAR NEUROBIOLOGY

A phase 3 trial of IV immunoglobulin for Alzheimer disease

(2017) Norman R. Relkin et al.   NEUROLOGY

Alzheimer's Disease and the Amyloid-β Peptide

(2017) M. Paul Murphy et al.   JOURNAL OF ALZHEIMERS DISEASE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease

(2016) Julia TCW et al.   Cold Spring Harbor Perspectives in Medicine

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

(2015) Kirsten L. Viola et al.   ACTA NEUROPATHOLOGICA

Role of RAGE in Alzheimer’s Disease

(2015) Zhiyou Cai et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Targeting Prodromal Alzheimer Disease With Avagacestat

(2015) Vladimir Coric et al.   JAMA Neurology

Clinical trial of an inhibitor of RAGE-A  interactions in Alzheimer disease

(2014) D. Galasko et al.   NEUROLOGY

Amino Acid Sequence and Structural Comparison of BACE1 and BACE2 Using Evolutionary Trace Method

(2014) Hoda Mirsafian et al.   TheScientificWorldJOURNAL

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage

(2014) Erik Portelius et al.   Alzheimers Research & Therapy

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease

(2014) Kelly Willemijn Menting et al.   Frontiers in Aging Neuroscience

Intravenous immunoglobulin and Alzheimer’s disease: what now?

(2013) David A Loeffler   Journal of Neuroinflammation

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

The mechanism of γ-Secretase dysfunction in familial Alzheimer disease

(2012) Lucía Chávez-Gutiérrez et al.   EMBO JOURNAL

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

(2012) Maria L Maccecchini et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

PPAR /RXR -Induced and CD36-Mediated Microglial Amyloid-  Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice

(2012) M. Yamanaka et al.   JOURNAL OF NEUROSCIENCE

Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor- -Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease

(2012) S. Mandrekar-Colucci et al.   JOURNAL OF NEUROSCIENCE

Amyloid Precursor Protein Processing and Alzheimer's Disease

(2011) Richard J. O'Brien et al.   Annual Review of Neuroscience

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

(2011) C. Harrington et al.   Current Alzheimer Research

Developing β-secretase inhibitors for treatment of Alzheimer’s disease

(2011) Arun K. Ghosh et al.   JOURNAL OF NEUROCHEMISTRY

PKC   Activation Prevents Synaptic Loss, A  Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice

(2011) J. Hongpaisan et al.   JOURNAL OF NEUROSCIENCE

Naturally Occurring Autoantibodies against  -Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease

(2011) R. Dodel et al.   JOURNAL OF NEUROSCIENCE

Robust Central Reduction of Amyloid-  in Humans with an Orally Available, Non-Peptidic  -Secretase Inhibitor

(2011) P. C. May et al.   JOURNAL OF NEUROSCIENCE

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2010) Michael Gold et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease

(2010) J. D. Brioni et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Episodic Memory System: Neurocircuitry and Disorders

(2009) Bradford C Dickerson et al.   NEUROPSYCHOPHARMACOLOGY

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING